Cystic fibrosis carrier screening

Area of Science:

• Medical Genetics
• Public Health
• Genetic Screening

Background:

• Carrier screening for cystic fibrosis (CF) has existed since the early 1990s.
• Despite availability, CF carrier screening programs are limited and not part of national health strategies.
• There is a need to evaluate the progress and future of population-based CF carrier screening.

Purpose of the Study:

• To describe carrier screening for cystic fibrosis (CF).
• To examine progress toward universal, population-based CF carrier screening programs.
• To consider the future of CF carrier screening with advancing genetic technologies and therapies.

Main Methods:

• Evidence-based commentary on population-based CF carrier screening.
• Review of peak body recommendations and existing CF carrier screening programs.
• Examination of attitudes among the general public, healthcare professionals, and individuals with CF.
• Analysis of health economic data.

Main Results:

• Few national programs exist for CF carrier screening, despite its long availability.
• Existing programs and recommendations vary, indicating a lack of standardized implementation.
• Attitudes towards screening are diverse across different stakeholder groups.
• Health economic data suggests potential benefits but requires careful consideration.

Conclusions:

• Universal population-based carrier screening for CF requires further development and integration into national health strategies.
• Advancements in genetic technologies and potential curative therapies necessitate a re-evaluation of CF screening approaches.
• Addressing stakeholder attitudes and economic factors is crucial for successful implementation of widespread CF carrier screening programs.